Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00557609 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study in Patients With MiT Tumors
A Phase 2 study, sponsored by ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA).
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT00557609 is a Phase 2 study that has completed, run by ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA). The registered enrollment target is 47 participants.
The verdict
NCT00557609, a Phase 2 study, has completed, sponsored by ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
This is a multi-center, single arm intended to evaluate the anti-tumor effect of ARQ 197 in patients with microphthalmia transcription factor associated (MiT) tumors. MiT tumors include clear cell sarcoma, alveolar soft parts sarcoma, and translocation associated renal cell carcinoma.
Interventions
- DRUG ARQ 197
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2007-10 |
| Est. Completion | 2011-02 |
| Phase | Phase 2 |
Sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)27 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00557609
The ClinicalTrials.gov registry entry for NCT00557609 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA), which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ARQ 197 is the first listed.
NCT00557609 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00557609 about?
NCT00557609 is a clinical study titled "Phase 2 Study in Patients With MiT Tumors". This is a multi-center, single arm intended to evaluate the anti-tumor effect of ARQ 197 in patients with microphthalmia transcription factor associated (MiT) tumors. MiT tumors include clear cell sarcoma, alveolar soft parts sarcoma, and translocation associated renal cell carcinoma.
What is the current status of trial NCT00557609?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2007-10. Estimated completion is 2011-02.
What interventions are being tested in trial NCT00557609?
The interventions under investigation include: ARQ 197 (DRUG).
Who is sponsoring clinical trial NCT00557609?
This trial is sponsored by ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA), which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.